Gilead Sciences, Inc.

GILDleader

Gilead Sciences is a research-based biopharmaceutical company that revolutionized the treatment of HIV and hepatitis C. Biktarvy has become the most prescribed HIV treatment globally, and the company is expanding aggressively into oncology through its Kite cell therapy division and antibody-drug conjugate platform.

共有:

⇄ Compare

製品と売上

製品別売上シェア

売上内訳 ($28.1B)

静的データ（リアルタイム財務ロード中…）

HIV (Biktarvy, Descovy) (55%)

Oncology (Trodelvy, Yescarta) (18%)

Liver Disease (HCV/HBV) (10%)

Veklury & Other (17%)

セグメント構成と主要顧客

製品詳細

Biktarvy45%

Leading single-tablet HIV regimen combining three antivirals

Veklury (Remdesivir)10%

Antiviral treatment for COVID-19 and emerging viral threats

Trodelvy/Cell Therapy25%

Oncology portfolio including ADCs and CAR-T via Kite Pharma

サプライチェーン関係

競合他社

Pfizer Inc.

Antiviral therapies

影響: Competing in antivirals

AbbVie Inc.

Oncology pipeline overlap

影響: Competing in oncology

パートナー

Moderna, Inc.

Potential mRNA-based HIV vaccine collaboration

影響: Research partnership

マクロ・市場概況

제약 / 바이오セクターニュース

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

次の主要イベント

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI分析

Gilead Sciences, Inc.のAIサプライチェーン分析を受けるには「AI分析を取得」をクリックしてください。

企業情報

本社所在地

Foster City, California, USA

設立

1987

従業員数

18,000+

ウェブサイト

gilead.com

セクター概況 — 제약 / 바이오

セクターニュース